Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Dose Response ; 18(2): 1559325820918762, 2020.
Article in English | MEDLINE | ID: mdl-32313525

ABSTRACT

OBJECTIVE: To investigate the protective effect of repaglinide on rat with atherosclerosis. METHODS: Sprague Dawley (SD) rats were divided into control, model, repaglinide, and metformin groups. In addition to the normal group, rats were given intraperitoneal injection of streptozotocin and high-fat diet (HFD). Meanwhile, repaglinide or metformin was administrated to the treatment rats, respectively, for 4 weeks. Serum, plasma, liver, epididymal fat, and aorta thoracica were obtained to observe the protective effect of repaglinide on rat with atherosclerosis. RESULTS: Compared to the control group, blood glucose was increased in the model group (P < .05), while it was decreased in the drug-administered groups. In addition, the levels of endothelin 1, TG, TC, low-density lipoprotein cholesterol, atherogenic index, liver index, and epididymal fat index were significantly increased, but the levels of high-density lipoprotein cholesterol, plasminogen activator inhibitor 1, and antiatherogenic index were decreased significantly in the model group compared to the control group (P < .05, respectively). And these effects were reversed by treatment with repaglinide (P < .05, respectively). CONCLUSION: Our results suggested that repaglinide may regulate the formation of early atherosclerosis through the abovementioned mechanisms.

SELECTION OF CITATIONS
SEARCH DETAIL
...